We are international

Velcade News Archive

04.29.05   VELCADE® for injection receives EU authorisation for second-line use in multiple myeloma
The European Commission has approved the use of VELCADE® (bortezomib) for Injection as a second-line treatment in patients with multiple myeloma.

03.25.05   FDA Approves VELCADE® for Use in Second-Line Multiple Myeloma
This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy. The approval was based on data from the randomized Phase III APEX study that compared single-agent VELCADE to high-dose dexamethasone. The study demonstrated a statistically significant survival advantage in the VELCADE arm of the study.

05.11.04   FDA Approves VELCADE® for Multiple Myeloma Treatment

06.11.04   New results for VELCADE® in previously untreated myeloma

06.11.04   New results for VELCADE® in relapsed myeloma